Analysis of factors causing hyperkalemia.

Area of Science:

• Nephrology
• Endocrinology
• Pharmacology

Background:

• Patients with chronic kidney disease (CKD) and diabetes mellitus (DM) are at increased risk of hyperkalemia.
• Hyperkalemia is a known adverse drug reaction of renin-angiotensin system (RAS) inhibitors, commonly prescribed for these patient populations.
• The clinical prevalence and contributing factors of hyperkalemia in these at-risk groups remain incompletely understood.

Purpose of the Study:

• To investigate the prevalence and risk factors associated with elevated serum potassium levels in patients with varying degrees of renal function.
• To assess the impact of diabetes mellitus and the use of RAS inhibitors on serum potassium levels.
• To identify independent predictors of hyperkalemia in a large patient cohort.

Main Methods:

• Retrospective analysis of 9,117 patients treated at Toranomon Hospital (January-October 2005) with serum creatinine < 5 mg/dL.
• Exclusion of patients on dialysis or using potassium-lowering medications (cation exchange resin, diuretics).
• Statistical analysis including step-wise multiple regression to identify correlations between serum potassium and clinical factors.

Main Results:

• Serum potassium levels significantly correlated with increasing serum creatinine and were higher in diabetic patients.
• Administration of angiotensin-II receptor blockers (ARB), angiotensin-converting-enzyme inhibitors (ACEI), or beta-blockers led to significant increases in serum potassium.
• A combination of diabetes and RAS inhibitor use showed a synergistic effect on increasing serum potassium in patients with milder renal impairment (serum creatinine < 1.5 mg/dL).
• Independent predictors of elevated serum potassium were: elevated serum creatinine, diabetes, ACEI use, ARB use, and age.

Conclusions:

• Reduced renal function, diabetes, RAS inhibitor therapy, and advanced age are independent risk factors for hyperkalemia.
• Particular caution is warranted when prescribing RAS inhibitors to diabetic patients, even those with relatively preserved renal function.
• RAS inhibitors can be safely administered to selected patients with diabetes or impaired renal function without inducing hyperkalemia, necessitating careful patient selection and monitoring.